TITLE

Anti-TNF-α therapy for renal amyloid as a complication of Crohn’s disease

AUTHOR(S)
Blackmur, J.P.; Chapman, F.A.; Bellamy, C.O.; Save, V.; Plevris, J.N.; Shand, A.G.; Whitworth, C.; Dhaun, N.
PUB. DATE
January 2014
SOURCE
QJM: An International Journal of Medicine;Jan2014, Vol. 107 Issue 1, p57
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
93398916

 

Related Articles

  • Treatment approaches for Crohn's disease. Chan, Y. Michael // Wellness Options;2006, Issue 27, p18 

    The author reports that Canada has the highest increase in the incidence of Crohn's disease (CD) in the world. In addition to short-term disabilities related to surgery for CD, there are considerable longer-term patient disabilities with high rates of unemployment. Treatment objectives are...

  • Severe deafness associated with Crohn’s disease and spondylarthropathy: successful treatment with anti-TNF. Jachiet, Marie; Lependu, Claire; Fragny, Dorothée; Mariette, Xavier; Lepajolec, Christine; Seror, Raphaèle // Rheumatology;Jun2013, Vol. 52 Issue 6, p1145 

    The article discusses the case of a man with severe deafness related to Crohn's disease (CD). It mentions that treatment with methylprednisolone pulses and high-dose oral prednisone resulted in an initial improvement but deafness worsened when prednisone doses were lowered. It also discusses...

  • Anti-tumour necrosis factor therapy in Crohn's disease: where are we now? van Deventer, S.J.H. // Gut;Sep2002, Vol. 51 Issue 3, p362 

    Background: Although familial clusters of Barrett's oesophagus and oesophageal adenocarcinoma have been reported, a familial predisposition to these diseases has not been systematically investigated. Aims: To determine whether Barrett's oesophagus and oesophageal (or oesophagogastric junctional)...

  • TNF-α −308A promoter polymorphism is associated with enhanced TNF-α production and inflammatory activity in Crohn’s patients with fistulizing disease. González, Segundo; Rodrigo, Luis; Martínez-Borra, Jesús; López-Vázquez, Antonio; Fuentes, Dolores; Niño, Pilar; Cadahía, Valle; Saro, Cristina; Dieguez, M. Angeles; López-Larrea, Carlos // American Journal of Gastroenterology;May2003, Vol. 98 Issue 5, p1101 

    : ObjectiveTumor necrosis factor-α (TNF-α) plays a key role in the inflammatory response and pathogenesis of Crohn’s disease (CD). TNF-α −308A polymorphism within the TNF-α gene promoter has been associated with enhanced TNF-α production in vitro. The aim of this...

  • Increased mucosal tumour necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Borruel, N.; Carol, M.; Casellas, F.; Antolín, M.; de Lara, F.; Espín, E.; Naval, J.; Guarner, F.; Malagelada, J.R. // Gut;Nov2002, Vol. 51 Issue 5, p659 

    Background and aims: Tumour necrosis factor α (TNF-α) plays a key role in the pathogenesis of intestinal inflammation in Crohn's disease. The effect of bacteria on TNF-α release by intestinal mucosa was investigated. Methods: Ileal specimens were obtained at surgery from 10 patients...

  • Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis. Arroyo, Vicente; Moreau, Richard // Nature Medicine;May2014, Vol. 20 Issue 5, p467 

    The article reflects on a study performed by J.A. O'Brien on role of prostaglandin E2 (PGE2) in immune suppression in patients with acutely decompensated cirrhosis. It mentions that the study included mass spectrometry, intravenous human serum albumin (HSA) administration, and analysis of LPS...

  • Anti TNF-a Treatment For Crohn's Disease: "M�nage � Trois.". Danese, Silvio // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p136 

    The author reflects on the effectiveness of anti-tumor necrosis factor-a (anti-TNFa) agents for the treatment of Crohn's disease. Studies have shown that anti-TNFa infliximab, adalimumab and certolizumab pegol are effective in preventing remission, healing mucosal lesions and fistulas and...

  • Adalimumab in Crohn's Disease.  // BioDrugs;2007, Vol. 21 Issue 2, p133 

    The article presents the author's views regarding the use of adalimumab for treatment of patients with Crohn's disease. He asserts that with the introduction of tumor necrosis factor-neutralizing antibodies such as infliximab and adalimumab, patients with Crohn' disease who start failing to...

  • Leczenie podtrzymujÄ…ce remisjÄ™ w nieswoistych zapaleniach jelit. Neubauer, Katarzyna; Paradowski, Leszek // Gastroenterologia Polska / Gastroenterology;2010, Vol. 17 Issue 2, p129 

    Maintenance therapy in inflammatory bowel disease (IBD) involves 5′-aminosalicylate derivatives, immunosuppressive drugs (azathioprine, 6-mercaptopurine, methotrexate), and biological agents, which are a breakthrough in the therapy of IBD. Among the biological agents currently available in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics